Every few months, someone on a brand team asks me some version of this: “How big does our patient population have to be before TV makes sense?” I wish there were a clean number. There isn’t. But there is a way to think about it.
The audience question
TV is a blunt instrument. You pay to reach everyone watching, and only a sliver of them have the condition you’re talking about. So the math is about waste: how much of your spend lands on people who could never be your patient?
A national broadcast or cable campaign can run into the tens of millions of dollars once you count media, production, and the compliance overhead of fair balance. For that to pay off, the condition has to be common enough that a meaningful share of viewers either have it or live with someone who does. That’s why you see TV spots for diabetes, depression, psoriasis, migraine, and COPD, and almost never for ultra-rare diseases.
Most people in the industry will tell you that conditions affecting several million patients are the natural home of national TV. But treat that as a rule of thumb, not a law. A few things shift the equation:
- Price per patient. A high-value therapy can justify TV with a smaller population because each new patient is worth more.
- Market dynamics. If patients actively ask doctors for a drug by name, TV gets more powerful. If a specialist makes every decision, it gets weaker.
- Competition. In a crowded category, you may need TV just to stay in the conversation.
If your population is smaller, you probably don’t need to abandon video. Connected TV, streaming, and targeted digital video let you aim at the people who matter without paying for the rest. It’s a trade of reach for precision, and for many smaller brands it’s the smarter one.
One more caveat: DTC advertising is under heavy regulatory and political scrutiny right now, and the rules have been shifting. Before you commit a TV budget, check with your regulatory and legal team on where things stand today.
Are unbranded websites worth it?
Yes, but only if you’re honest about what they’re for. An unbranded site (sometimes called a disease awareness site) talks about a condition without naming a product. Think symptom checkers, plain-language explanations, and questions to ask your doctor. Because they make no product claims, they aren’t held to the same fair balance rules as branded promotion. That’s the tempting part, and also the trap. Regulators have little patience for a “disease education” site that’s really a billboard in disguise.
Done well, these sites earn their keep in a few ways:
- They meet people early. Someone Googling “why am I always exhausted” isn’t ready for a brand name. They’re looking for answers, and you get to be the trustworthy one.
- They build trust. A site that actually helps, without a hard sell, makes people more receptive later.
- They feed the doctor conversation. The best ones help patients show up to an appointment with better questions, which is DTC’s real goal.
- They support search. Informational content captures the huge volume of searches that happen before anyone knows a treatment exists.
The weakness is measurement. It’s hard to draw a straight line from a symptom-checker visit to a prescription, so these sites often get undervalued in budget meetings. Judge them on engagement, return visits, and downstream behavior rather than last-click conversions.
Don’t ask “is my audience big enough?” in isolation. Ask whether the cost of reaching a patient through TV makes sense given what a patient is worth to you. And don’t write off unbranded sites as a nice-to-have. For many brands, they’re the front door.

